MONMOUTH JUNCTION, N.J., Nov. 20, 2019 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today a $492,000 award in support of the project entitled “Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.” The award will accelerate the development of DiamiR’s targeted diagnostic technology for detection and prediction of Alzheimer’s disease (AD) progression. The award is provided by the Alzheimer’s Drug Discovery Foundation (ADDF) Diagnostics Accelerator, a fund set up in collaboration with Bill Gates and other philanthropic partners.